Skip to main content

Table 4 Risk of SPM after lung HGNEC, stratified by race

From: Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)

  Observed Expected O/E 95% CI Excess risk
White
All Sites 1187 782.04 1.52 1.43–1.61 81.89
All Solid Tumours 1080 695.27 1.55 1.46–1.65 77.8
Oral Cavity and Pharynx 26 17.87 1.45 0.95–2.13 1.64
 Floor of Mouth 8 0.99 8.11 3.5–15.98 1.42
 Oropharynx 4 0.68 5.9 1.61–15.09 0.67
Digestive System 195 140.5 1.39 1.20–1.60 11.02
 Splenic Flexure 5 1.6 3.13 1.02–7.30 0.69
 Pancreas 40 22.39 1.79 1.28–2.43 3.56
Respiratory System 568 127.47 4.46 4.10–4.84 89.08
Breast 78 110.42 0.71 0.56–0.88 −6.56
Female Genital System 17 42.44 0.4 0.23–0.64 −5.14
Male Genital System 46 120.8 0.38 0.28–0.51 −15.13
Urinary System 102 68.89 1.48 1.21–1.80 6.7
 Urinary Bladder 62 41.77 1.48 1.14–1.90 4.09
 Kidney 36 23.49 1.53 1.07–2.12 2.53
All Lymphatic and Hematopoietic Diseases 84 67.83 1.24 0.99–1.53 3.27
 Leukemia 59 21.46 2.75 2.09–3.55 7.59
Black
All Sites 122 78.39 1.56 1.29–1.86 85.42
All Solid Tumours 114 70.91 1.61 1.33–1.93 84.42
Oral Cavity and Pharynx 2 1.55 1.29 0.16–4.67 0.89
 Gum and Other Mouth 2 0.22 9.1 1.1–32.89 3.49
Digestive System 27 16.98 1.59 1.05–2.31 19.62
 Esophagus 4 0.89 4.5 1.23–11.52 6.09
Respiratory System 54 13.17 4.1 3.08–5.35 79.97
Male Genital System 10 18.97 0.53 0.25–0.97 −17.58
Kidney 7 2.74 2.55 1.03–5.26 8.34
Adrenal Gland 1 0.02 41.01 1.04–228.51 1.91
Leukemia 4 1.48 2.7 0.73–6.91 4.93
Other (American Indian/AK Native, Asian/Pacific Islander)   
All Sites 52 26.33 1.97 1.47–2.59 108.64
All Solid Tumours 47 23.6 1.99 1.46–2.65 99.04
 Oral Cavity and Pharynx 2 0.62 3.24 0.39–11.7 5.85
 Pharynx 2 0.19 10.47 1.27–37.81 7.66
 Oropharynx 1 0.01 69.8 1.77–388.92 4.17
Digestive System 5 7.56 0.66 0.21–1.54 −10.82
Respiratory System 28 4.23 6.63 4.4–9.58 100.62
Leukemia 3 0.56 5.4 1.11–15.77 10.34